Andere Kunden interessierten sich auch für
![Novel Combination Therapies for Prostate Cancer Treatment]( "Novel Combination Therapies for Prostate Cancer Treatment")
Novel Combination Therapies for Prostate Cancer Treatment23,99 €![A novel therapeutic approach for the treatment of cerebral palsy]( "A novel therapeutic approach for the treatment of cerebral palsy")
A novel therapeutic approach for the treatment of cerebral palsy23,99 €![A Novel Therapeutic Approach for the Treatment of Brain Atrophy]( "A Novel Therapeutic Approach for the Treatment of Brain Atrophy")
A Novel Therapeutic Approach for the Treatment of Brain Atrophy23,99 €![A novel therapeutic approach for myelomeningocele]( "A novel therapeutic approach for myelomeningocele")
A novel therapeutic approach for myelomeningocele26,99 €![Therapeutic drug monitoring of antiretroviral agents]( "Therapeutic drug monitoring of antiretroviral agents")
Therapeutic drug monitoring of antiretroviral agents38,99 €![A novel therapeutic approach for idiopathic mental retardation]( "A novel therapeutic approach for idiopathic mental retardation")
A novel therapeutic approach for idiopathic mental retardation23,99 €![New Therapeutic Agents from Pakistan]( "New Therapeutic Agents from Pakistan")
New Therapeutic Agents from Pakistan32,99 €
Standard hormonal therapy with currently available
anti-androgens and LHRH analogs becomes ineffective
in the hormone-refractory stage of prostate cancer
due to the changes in androgen receptor signaling
axis in prostate cancer cells. To develop effective
therapies against hormone-refractory prostate
cancer,
novel agents targeting multiple points at the
cellular signaling cascades are needed in order to
produce the maximal therapeutic efficacy against
late
stage prostate cancer. In this dissertation work, we
have presented the design and development of novel
agents targeting three key signaling pathways
towards
their ultimate development into the effective
therapies against hormone refractory prostate
cancer.
Specifically, we have discovered and designed a
diverse array of novel molecules targeting the AR
signaling pathway, the sarco-endoplasmic reticulum
calcium ATPase pump driven calcium homeostasis and
the proteolytic activity of prostate specific
antigen
.
anti-androgens and LHRH analogs becomes ineffective
in the hormone-refractory stage of prostate cancer
due to the changes in androgen receptor signaling
axis in prostate cancer cells. To develop effective
therapies against hormone-refractory prostate
cancer,
novel agents targeting multiple points at the
cellular signaling cascades are needed in order to
produce the maximal therapeutic efficacy against
late
stage prostate cancer. In this dissertation work, we
have presented the design and development of novel
agents targeting three key signaling pathways
towards
their ultimate development into the effective
therapies against hormone refractory prostate
cancer.
Specifically, we have discovered and designed a
diverse array of novel molecules targeting the AR
signaling pathway, the sarco-endoplasmic reticulum
calcium ATPase pump driven calcium homeostasis and
the proteolytic activity of prostate specific
antigen
.